Gynecologic and hormonal effects of raloxifene in premenopausal women

Fertility and Sterility

Volumn 88, Issue 6, 2007, Pages 1637-1644

  Premkumar, Ahalya ^a   Venzon, David J ^b   Avila, Nilo ^a   Johnson, Diane V ^a   Remaley, Alan T ^a   Forman, Michele R ^b   Eng Wong, Jennifer ^c   Zujewski, JoAnne ^c   Stratton, Pamela ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Medical Oncology Branch   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

breast cancer; endometrium; hormones; ovary; premenopausal women; Raloxifene

Indexed keywords

CALCIUM CARBONATE; ESTROGEN; FOLLITROPIN; HORMONE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; RALOXIFENE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; DRUG EFFECT; ECHOMAMMOGRAPHY; ENDOMETRIUM; ENDOMETRIUM POLYP; FEMALE; FOLLICLE CYST; FOLLICULAR PHASE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MEDICAL RESEARCH; MENSTRUAL CYCLE; MENSTRUATION; OVARY; OVULATION; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STIMULATION; THICKNESS; TUMOR VOLUME; UTERUS; UTERUS MYOMA;

ADULT; BREAST NEOPLASMS; CALCIUM CARBONATE; CARCINOMA; DEHYDROEPIANDROSTERONE SULFATE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENITALIA, FEMALE; GONADAL STEROID HORMONES; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; POLYPS; PREMENOPAUSE; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERINE DISEASES;

EID: 36849074257     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.01.095     Document Type: Article

References (43)

1. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 97 (2005) 1652-1662
2. Rayter Z., Gazet J.C., Shepherd J., Trott P.A., Fisher C., Svensson W.E., et al. Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol 20 (1994) 134-140
3. Hulka C.A., and Hall D.A. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. AJR Am J Roentgenol 160 (1993) 809-812
4. Wolf D.M., and Jordan V.C. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 45 (1992) 118-128
5. Colacurci N., De Seta L., De Franciscis P., Mele D., Fortunato N., and Cassese S. Tamoxifen effects on endometrium. Panminerva Med 42 (2000) 45-47
6. Ross D., and Whitehead M. Hormonal manipulation and gynaecological cancer: the tamoxifen dilemma. Curr Opin Obstet Gynecol 7 (1995) 63-68
7. Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Ashley S.E., Cosgrove D.O., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343 (1994) 1318-1321
8. King C.M. Tamoxifen and the induction of cancer. Carcinogenesis 16 (1995) 1449-1454
9. Premkumar A., Avila N., Dwyer A., Noone M., Murphy-Johnson D., McAtee N., et al. Effects of tamoxifen on the ovaries. Evaluation with gray-scale and color Doppler ultrasound. J Womens Imaging 1 (1999) 18-23
10. Cohen I., Rosen D.J., Altaras M., Beyth Y., Shapira J., and Yigael D. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. Br J Cancer 69 (1994) 620-621
11. Powles T.J., Jones A.L., Ashley S.E., O'Brien M.E., Tidy V.A., Treleavan J., et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31 (1994) 73-82
12. Groom G.V., and Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70 (1976) 421-428
13. Schwartz L.B., Rutkowski N., Horan C., Nachtigall L.E., Snyder J., and Goldstein S.R. Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation. J Ultrasound Med 17 (1998) 699-703
14. Boss S.M., Huster W.J., Neild J.A., Glant M.D., Eisenhut C.C., and Draper M.W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177 (1997) 1458-1464
15. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
16. Jolly E.E., Bjarnason N.H., Neven P., Plouffe Jr. L., Johnston Jr. C.C., Watts S.D., et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10 (2003) 337-344
17. Shah A.S., Scheele W.H., Glant M.D., and Fugere P. Raloxifene HCl is not stimulatory in the endometrium as assessed by the Blaustein criteria and an estrogenicity scoring system. Prim Care Update Ob Gyns 5 (1998) 167
18. Grady D., Ettinger B., Moscarelli E., Plouffe Jr. L., Sarkar S., Ciaccia A., et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104 (2004) 837-844
19. Maia Jr. H., Oliveira M., Almeida M., and Coutinho E.M. Growth of an endometrial polyp in a postmenopausal patient using raloxifene. Gynaecol Endos 9 (2000) 117-121
20. Tsalikis T., Zepiridis L., Zafrakas M., Dinas K., and Bontis J. Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene. Maturitas 51 (2005) 215-218
21. Baker V.L., Draper M., Paul S., Allerheiligen S., Glant M., Shifren J., et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 83 (1998) 6-13
22. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278 (1997) 1242-1250
23. Eng-Wong J., Reynolds J.C., Venzon D., Liewehr D., Gantz S., Danforth D., et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 91 (2006) 3941-3946
24. Faupel-Badger J.M., Prindiville S.A., Venzon D., Vonderhaar B.K., Zujewski J.A., and Eng-Wong J. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 1153-1158
25. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
26. Parsons A.K. Imaging the human corpus luteum. J Ultrasound Med 20 (2001) 811-819
27. Hapangama D., Glasier A.F., and Baird D.T. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. Contraception 63 (2001) 123-129
28. Fisher S.A., Reid R.L., Van Vugt D.A., and Casper R.F. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 78 (2002) 280-285
29. Neven P., Lunde T., Benedetti-Panici P., Tiitinen A., Marinescu B., de Villiers T., et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. BJOG 110 (2003) 157-167
30. Christodoulacos G., Panoulis C., Botsis D., Rizos D., Kassanos D., and Creatsas G. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. Maturitas 42 (2002) 77-84
31. DeWaay D.J., Syrop C.H., Nygaard I.E., Davis W.A., and Van Voorhis B.J. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 100 (2002) 3-7
32. Reslova T., Tosner J., Resl M., Kugler R., and Vavrova I. Endometrial polyps. A clinical study of 245 cases. Arch Gynecol Obstet 262 (1999) 133-139
33. Guven M.A., Bese T., and Demirkiran F. Comparison of hydrosonography and transvaginal ultrasonography in the detection of intracavitary pathologies in women with abnormal uterine bleeding. Int J Gynecol Cancer 14 (2004) 57-63
34. Berliere M., Charles A., Galant C., and Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 91 (1998) 40-44
35. Cramer S.F., and Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 94 (1990) 435-438
36. Newbold R.R., DiAugustine R.P., Risinger J.I., Everitt J.I., Walmer D.K., Parrott E.C., et al. Advances in uterine leiomyoma research: conference overview, summary, and future research recommendations. Environ Health Perspect 108 Suppl 5 (2000) 769-773
37. Palomba S., Orio Jr. F., Morelli M., Russo T., Pellicano M., Zupi E., et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 87 (2002) 3603-3608
38. Palomba S., Sammartino A., Di Carlo C., Affinito P., Zullo F., and Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 76 (2001) 38-43
39. Jirecek S., Lee A., Pavo I., Crans G., Eppel W., and Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 81 (2004) 132-136
40. Santoro N., Isaac B., Neal-Perry G., Adel T., Weingart L., Nussbaum A., et al. Impaired folliculogenesis and ovulation in older reproductive aged women. J Clin Endocrinol Metab 88 (2003) 5502-5509
41. Lumsden M.A., West C.P., and Baird D.T. Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clin Endocrinol (Oxf) 31 (1989) 335-343
42. Cohen I., Figer A., Tepper R., Shapira J., Altaras M.M., Yigael D., et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 72 (1999) 202-207
43. Caleffi M., Fentiman I.S., Clark G.M., Wang D.Y., Needham J., Clark K., et al. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 119 (1988) 335-339